Preloaded Autoinjector | Oxytocin | 3ml Pen | 10mg

The oxytocin pen is a preloaded 3ml research device holding the cyclic nonapeptide CYIQNCPLG-NH2 in solution at 3.33mg/ml, giving 10mg in total. Unlike almost every compound sold in this format, oxytocin has never been marketed as a lyophilized powder, so the real difference here is concentration: this device is roughly 200 times stronger than any licensed ampoule.

Specification Table

What Changes When Oxytocin Ships at 3.33 mg/ml?

For most compounds in this catalogue the interesting question is what happens when a dry powder is put into water. Oxytocin has never been sold dry: every licensed product is a ready-to-use aqueous solution, so the question here is what happens at 200 times the licensed strength.

Start with the chemistry that is already well mapped. Hawe and colleagues heated oxytocin at 40 to 80°C across pH 2.0, 4.5, 7.0 and 9.0 in 2009 and found first-order loss with Arrhenius behaviour, an activation energy of 116.3 kJ/mol at pH 4.5, and a stability ranking of pH 4.5 above 2.0 above 7.0 above 9.0. The product set changed with pH. At pH 2 the peptide deamidated. Between pH 4.5 and 9 it built trisulfides and tetrasulfides, disulfide-linked dimers, dityrosine-linked dimers and larger aggregates.

Four features of the sequence explain that. The Cys1-Cys6 disulfide closing the 20-membered tocin ring can scramble, undergo beta-elimination to dehydroalanine and persulfide species, or open and re-form between molecules rather than within one. Gln4, Asn5 and the C-terminal glycinamide are three separate amide groups that hydrolyse to acids, each adding 1 dalton. Tyr2 is the chromophore and the site of dityrosine cross-linking under illumination. Pro7 isomerises between cis and trans conformers, which is not degradation but complicates any chromatogram read as a purity figure.

The fifth feature is the one worth dwelling on, and it comes from Wisniewski and colleagues in 2013. They compared oxytocin with analogues that survive heat far better, and the structural difference is the free amine on Cys1. Carbetocin lacks that amine and replaces the disulfide with a carba bridge; desmopressin also lacks it. Removing the free N-terminal amine removes the intramolecular route through which the peptide attacks its own disulfide. Oxytocin still has it, which is why heat-stable analogues had to be invented rather than reformulated.

Now put concentration back into the picture. Dimer and trimer formation is bimolecular: the rate depends on the square of peptide concentration, while deamidation and simple hydrolysis do not. Every published degradation study on this molecule was run at or below 1 mg/ml, close to the 8 to 17 micrograms per millilitre of a clinical ampoule. In an oxytocin pen at 3.33 mg/ml the covalent-dimerisation term is weighted far more heavily than in any of that work, and nobody has published a rate constant for it.

What the Approved Formulations Reveal

Two regulators looked at the same molecule and reached different conclusions about how to keep it intact, which is unusual enough to be worth reading closely.

US Pitocin, NDA 018261, approved on 19 November 1980, is 10 USP units per millilitre with 0.5 percent chlorobutanol, 1.65 mg acetic acid and 0.16 mg ammonium acetate per millilitre, a target pH of 3.5, and storage at 20 to 25°C. The Fresenius Kabi product under NDA 018248 is also 10 units/ml, acetic acid to pH 3.0 to 5.0, stored at 20 to 25°C with the instruction not to permit freezing. UK concentrates from hameln and Panpharma at 5 and 10 IU/ml use acetate buffer with sodium chloride, are stored at 2-8°C protected from light, and carry three to five year shelf lives.

Both routes land on acetate near pH 3.5 to 4.5, the Hawe optimum, and neither uses the formulation that performs best in the laboratory. Avanti and colleagues showed in 2011 that 10 mM citrate at pH 4.5 with 2 to 50 mM calcium, magnesium or zinc kept about 80 to 90 percent of the peptide intact after four weeks at 55°C, and their 2012 follow-up traced that to suppression of the cysteine-mediated intermolecular reactions. The same metal ions in acetate gave little benefit, and every licensed product uses acetate. That gap is why Torloni and colleagues found substandard oxytocin so widely in low- and middle-income countries in 2016, and why heat-stable carbetocin was developed at all.

Oxytocin Solution Stability: What Has Been Measured

Oxytocin solution stability is better characterised than that of any other compound sold in this device format, and none of that work was done at this concentration. The distinction matters more than the volume of literature suggests.

What is known: degradation kinetics across four pH values (Hawe 2009); the identity of the products by size-exclusion and reversed-phase chromatography with mass detection; a stabilisation strategy using citrate and divalent metals (Avanti 2011, 2012, and the 2013 extension to aspartate buffer); the role of the free N-terminal amine (Wisniewski 2013); and field evidence that the cold chain fails in practice (Torloni 2016).

What is not known for this product: the buffer, the pH, the presence or absence of a divalent metal, and any rate constant at 3.33 mg/ml. Studies of oxytocin solution stability at clinical strength cannot simply be scaled up, because the dominant route at high concentration is the second-order one. A researcher who wants a defensible answer has to run the assay on the device rather than read it off the literature.

Oxytocin IU to mg: What One Oxytocin Pen Holds

The oxytocin iu to mg conversion is fixed by the USP potency assignment: 1 IU is 1.67 micrograms, so 1 mg is about 600 IU and this 10 mg device holds about 6,000 IU.

The rest follows arithmetically. Concentration is 10 divided by 3, or 3.33 mg/ml, which is 3,333 micrograms per millilitre and about 2,000 IU/ml. Divided by the molecular weight of 1007.19, that is 3.31 mM. One 0.01 ml graduation carries 33.3 micrograms, 33.1 nanomoles, about 20 IU. A 0.1 ml movement carries 333 micrograms, 331 nanomoles, about 200 IU.

Those numbers only mean something against a reference point. Pitocin is 10 IU/ml, so a single 0.01 ml increment of this device contains what 2 ml of Pitocin contains. Intranasal quantities in behavioural research papers run 24 to 40 IU, which is 40 to 67 micrograms, or between one and two increments. At the other end, oxytocin receptor half-maximal effect concentrations sit in the low nanomolar range, and getting from 3.31 mM to 10 nM is a 331,000-fold serial dilution. The dilution calculator is faster than doing that by hand, and repeating the oxytocin iu to mg step at each stage is where most arithmetic errors enter.

Oxytocin Pen vs Vial: What Actually Differs

The usual pen-versus-vial argument is about reconstitution, and for this molecule that argument mostly evaporates, because the vial presentation is a solution too. The oxytocin pen vs vial choice here comes down to concentration, headspace and how many times the reservoir is entered.

A 2mg vial of the same peptide and this device differ in how often the seal is punctured and in how much air sits above the liquid between draws, both of which feed oxidative coupling between molecules. Repeated puncture also raises a microbiological question no certificate of analysis answers, since neither preparation lists a preservative system.

What the device does well is deliver equivalent volumes repeatedly without transfer steps. The general trade-off is set out in the pen and vial comparison, and the rest of the range sits on the preloaded autoinjector category page. An intranasal preparation of the same molecule covers work where route rather than quantity is the variable.

What the Product Record Does Not State

Four fields are absent, and for this molecule the pH is the one that changes the answer to everything else.

Solution pH is not published on the product record. Given a measured stability ranking of pH 4.5 above 2.0 above 7.0 above 9.0, and an eightfold difference in half-life across that range in the Hawe data, the difference between a formulation at pH 4.5 and one at pH 7 is not a detail. Excipient system: not published on the product record. Confirm against certificate of analysis, and ask specifically whether a divalent metal or citrate is present, because that single answer decides whether the Avanti stabilisation applies.

Solution appearance and fill date are also absent. For an oxytocin pen the fill date is the origin of the degradation clock, and for this peptide that clock runs faster at higher concentration than any published dataset covers.

Verifying an Oxytocin Pen and Its Contents

Size-exclusion chromatography is the single most informative measurement on this compound, because the covalent dimers and trimers that dominate its degradation are exactly what that method separates.

Ultraviolet absorbance gives a concentration estimate but a weak one, since Tyr2 is the only aromatic residue and there is no tryptophan. Read the spectrum rather than one wavelength, watching for absorbance above 300 nm where dityrosine products appear.

Mass spectrometry catches part of the picture and misses part. Deamidation of Gln4, Asn5 or the glycinamide adds 1 dalton per site, so mono- and bis-deamidated species are visible as plus 1 and plus 2 satellites on the 1007.19 parent. Trisulfide adds 32. Disulfide scrambling within a single molecule changes no mass at all, which is why a chromatographic method has to sit alongside the spectrometer. An Ellman free-thiol assay answers a related question cheaply: intact material should show essentially none.

Let the cartridge equilibrate to ambient temperature before actuating, and verify delivered volume gravimetrically once against a tared vessel. Inspect each draw against a white card for particulate and haze, which at this concentration would suggest aggregate rather than contamination.

Can You Buy Oxytocin as a Research Chemical?

The question “can you buy oxytocin” has a legal answer that differs from the commercial one. Oxytocin is a prescription drug substance in the United States, the United Kingdom and the European Union, and describing a preparation as a research chemical does not alter that status.

The approvals are specific and easy to check. Pitocin, oxytocin injection USP 10 units/ml, sits under NDA 018261 with Par Health USA and was approved on 19 November 1980; a second product from Fresenius Kabi holds NDA 018248. The United Kingdom licenses 5 and 10 IU/ml infusion concentrates from hameln, Panpharma, Wockhardt and Esteve, and the molecule is on the WHO Essential Medicines List. No intranasal product holds FDA approval. On the 503B bulk-substance list updated 21 March 2025 the substance appears as Category 1, flagged as a component of an approved drug, so a compounder under section 503A may prepare it for an individual prescription but not as essentially a copy of Pitocin. A 3.33 mg/ml multi-dose device has no approved counterpart anywhere.

Oxytocin is not a controlled substance and is not named on the WADA Prohibited List. This particular preparation is supplied for laboratory research only and is not for administration to humans or animals.

What the Clinical Literature Covers and What It Leaves Out

The trial base for oxytocin is one of the largest for any peptide, and none of it was conducted at anything resembling this concentration, route or presentation.

The published record concerns induction and augmentation of labour and control of postpartum haemorrhage, summarised in Cochrane reviews and WHO uterotonic recommendations. Those trials used hospital ampoules at 5 to 10 IU/ml intravenously or intramuscularly under monitoring, never a multi-dose device, a subcutaneous route or milligram quantities. Reported pharmacokinetics are short: a half-life of 1 to 6 minutes on the Pitocin label and 3 to 20 minutes in the UK summary of product characteristics, a volume of distribution of 12.2 litres, negligible protein binding, and metabolic clearance of about 20 ml/kg/min in pregnancy, shared between liver, kidney and circulating oxytocinase.

Receptor pharmacology is set out by Gimpl and Fahrenholz in their 2001 review: a class A G-protein-coupled receptor signalling through Gq/11 and phospholipase C to raise intracellular calcium, with lower-affinity activity at vasopressin V1a receptors that accounts for transient hypotension and tachycardia after intravenous bolus administration. The peripheral peptide crosses the blood-brain barrier poorly, which is the standing objection to reading behavioural findings from peripheral administration. Central circuits are covered in the article on oxytocin and neuronal circuits.

Adverse findings on the approved labels are specific and serious: uterine hyperstimulation and rupture, fetal distress, water intoxication and hyponatraemia with prolonged infusion, hypotension and tachycardia after intravenous bolus, arrhythmia, nausea and anaphylaxis. The Pitocin label states the product is not indicated for elective induction. All of that was recorded at 10 IU/ml under clinical monitoring, and nothing has been published on the exposure this device carries.

What Are the Approved Obstetric Uses of This Peptide Hormone?

Oxytocin is a nonapeptide hormone made in the hypothalamus and released from the posterior pituitary gland, and the approved products containing it are obstetric medicines. It works as a peptide hormone in the circulation and as a neuropeptide in the brain, and those two roles are studied by different fields with different methods. In the United States the FDA-approved indications are medical, not elective, induction of labour, stimulation or reinforcement of labour in uterine inertia, control of postpartum bleeding, and adjunctive use in incomplete or inevitable abortion. The mechanism is direct: receptors on uterine smooth muscle multiply enormously through late pregnancy, and agonism at them produces uterine contractions strong enough to be titrated against a monitor.

The second approved use concerns lactation rather than childbirth. Contraction of myoepithelial cells around the alveoli of the mammary glands produces milk ejection, the reflex commonly called milk letdown, and Syntocinon Nasal Spray was approved in the United States in 1960 to assist initial postpartum milk ejection and was discontinued in 1997 for commercial reasons. Breastfeeding difficulty is where that indication sat. The reflex itself is a normal part of physiology, triggered by suckling through a spinal afferent pathway to the hypothalamus.

Obstetric dosing is where the difference between a medicine and a research chemical becomes concrete. Approved labour induction protocols start at milliunit-per-minute infusion rates, titrated upward against contraction frequency with continuous fetal monitoring, in a hospital, by staff trained to stop. Obstetric labels carry warnings about uterine rupture, water intoxication from the antidiuretic effect at high infusion rates, and fetal distress. Those obstetric side effects are documented because a regulated product generated them in a monitored setting.

Everything else this molecule is used for is off-label or investigational. That includes every behavioural application below, and it is worth stating that an off-label use of an approved obstetric product and a research chemical bought as a solution are two different situations with two different safety positions.

Why Is It Called the Love Hormone, and What Does the Evidence Show?

The love hormone name comes from animal work, chiefly on prairie voles, where oxytocin and vasopressin signalling in the nucleus accumbens and related circuits underpins pair bonding in a monogamous species. Manipulating the pathway changed partner preference. That is a real and reproducible finding in that animal, and it is the origin of almost all the social bonding language attached to the molecule.

Human work took that idea to social behavior generally. Studies reported changes in trust, generosity, empathy, gaze toward the eye region, and recognition of social cues after administration, with functional imaging showing reduced amygdala reactivity to threatening faces and altered hippocampus and nucleus accumbens responses. As a neuropeptide it acts through a single receptor, OXTR, which is also bound by vasopressin at higher concentrations, and vasopressin has its own receptors with partly overlapping effects, so the two systems are hard to separate pharmacologically.

Replication has been the problem. Many of the early social cognition findings came from small samples with flexible analysis, and larger pre-registered studies have often failed to reproduce them. Meta-analyses of the trust literature report effect sizes close to zero once publication bias is modelled. Anxiety findings are similar: an anxiolytic effect appears in some paradigms and reverses in others, and cortisol responses to social stress have moved in both directions across studies. Cortisol is the marker most often used to index stress responses in this literature, which makes those inconsistent cortisol results harder to explain away than the behavioural ones. Social cognition remains an active research area rather than a settled one, and the honest summary is that the animal biology is solid while the human behavioural pharmacology is contested.

How Does This Interact With Gonadal Steroids?

Closely enough that the two are hard to study apart, though the mechanism is better established in rodents than in people. A functional oestrogen response element was identified in the rat Oxtr promoter, and receptor density in rodents is oestrogen-regulated, with testosterone contributing through aromatisation to oestradiol. Equivalent regulation of the human OXTR gene is not established: much of the work cited for it concerns the OXT gene, which encodes the peptide, rather than the receptor gene. Treat the steroid-control account as animal biology with a human inference attached.

Behavioural studies have repeatedly framed the two hormones as opposing. Testosterone administration reduces measured empathy and increases threat-related amygdala reactivity in several paradigms, while this peptide tends to move both in the other direction, and a number of papers have tested them head to head on that basis. Baseline testosterone has also been reported to moderate the response to intranasal administration, with the same dose producing different effects in men at different testosterone levels. Those interaction findings carry the same replication caveats as the rest of the human literature.

Sexual activity raises both, which complicates causal reading in either direction. Testosterone is the more thoroughly characterised of the two as a circulating hormone, with assays, reference ranges and decades of clinical use, and none of that applies here. The oxytocin peptide has no approved use outside obstetrics, and no diagnostic reference range for the purposes any behavioural study is measuring. Unlike a classical neurotransmitter released into a synapse and cleared in milliseconds, the oxytocin peptide is released from dendrites and diffuses widely, which is part of why central and peripheral measurements correlate so poorly.

What Do the Intranasal Trials Actually Show?

Intranasal delivery is the route almost every behavioural study uses, on the assumption that some fraction reaches the brain along olfactory and trigeminal pathways rather than through the circulation. That assumption is defensible and imperfectly quantified: intranasal administration does raise central concentrations in animal work, but the fraction is small and variable, and comparing an intranasal dose in one study with an intranasal dose in another is harder than the shared units suggest. Sublingual and buccal routes have been tried with less characterisation still.

The two largest indications tested are autism and schizophrenia, and both have produced discouraging results at scale. In autism, a multi-site randomised trial published in 2021 gave intranasal oxytocin to children and adolescents for 24 weeks and found no benefit over placebo on social withdrawal measures, after a decade of smaller positive studies. In schizophrenia, trials targeting negative symptoms have been repeatedly run and repeatedly null, with a pooled effect of about -0.26 standard deviations across nine randomised trials and a confidence interval crossing zero. Meta-analysis of social cognition in schizophrenia finds an overall effect near zero, with a small and unstable signal on higher-level social cognition tasks that has not held up as a clinical result. Schizophrenia remains one of the more studied applications precisely because the early signals looked promising.

Other applications have smaller literatures. Trials in obesity have reported modest reductions in caloric intake over short periods. Studies in social anxiety and in post-traumatic stress have been mixed, and stress responses measured physiologically rather than by questionnaire have been the least consistent of all. An oxytocin nasal spray sold outside a trial has no established dosing, and reported side effects from the trial literature are mostly mild, headache and nasal irritation being commonest, with the caveat that most studies were short and none was powered for safety. Sold as a research chemical, this material has no label, no dosing schedule derived from a trial of it, and no approved use of any kind.

Published Literature

References below were confirmed against publisher records or PubMed before listing. They describe the molecule and its aqueous behaviour; none describes this device.

1. Hawe A, Poole R, Romeijn S, et al. Towards heat-stable oxytocin formulations: analysis of degradation kinetics and identification of degradation products. Pharm Res. 2009;26(7):1679-1688. DOI: 10.1007/s11095-009-9878-2
2. Avanti C, Amorij JP, Setyaningsih D, et al. A new strategy to stabilize oxytocin in aqueous solutions: I. The effects of divalent metal ions and citrate buffer. AAPS J. 2011;13(2):284-290. DOI: 10.1208/s12248-011-9268-7
3. Avanti C, Permentier HP, van Dam A, et al. A new strategy to stabilize oxytocin in aqueous solutions: II. Suppression of cysteine-mediated intermolecular reactions by a combination of divalent metal ions and citrate. Mol Pharm. 2012;9(3):554-562. DOI: 10.1021/mp200622z
4. Wisniewski K, Finnman J, Flipo M, et al. On the mechanism of degradation of oxytocin and its analogues in aqueous solution. Biopolymers (Pept Sci). 2013;100(4):408-421. DOI: 10.1002/bip.22260
5. Torloni MR, Gomes Freitas C, Kartoglu UH, et al. Quality of oxytocin available in low- and middle-income countries: a systematic review of the literature. BJOG. 2016;123(13):2076-2086. DOI: 10.1111/1471-0528.13998
6. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81(2):629-683. DOI: 10.1152/physrev.2001.81.2.629
7. Pitocin (oxytocin injection, USP) prescribing information, Par Health USA, rev. 03/2026, NDA 018261.
8. Oxytocin 5 IU/ml concentrate for solution for infusion, summary of product characteristics, Panpharma UK.

Frequently Asked Questions